Loading...

SANA SANA BIOTECHNOLOGY INC Capital Structure Changes 8-K Filing

SN B

SN

SANA BIOTECHNOLOGY INC

(SANA)

2025 8-K

Financial Results Announced

Management Change

Director Resignation

Equity Offerings

Clinical Updates

Product Expansion

Equity Offerings

Financial Results

Corporate Presentation

Financial Results

Management Changes

Management Change

Earnings Reports

Annual Meeting Results

Financial Results Announcement

Resignation of Executive

Financial Results Announcement

Public Offering

Financial Update

Conference Presentation

Financial Results Announcement

Portfolio Update and Workfo...

Regulation FD Disclosure

Termination of Lease Agreement

Financial Results Announcement

Annual Meeting Results

Presentation at Conference

Earnings Reports

Resignation of Executive

Management Changes

Financial Results Announcement

FDA Clearance for First-in-...

FDA Clearance for First-in-...

Regulation FD Disclosure

External Links:

On May 8, 2025, Sana Biotechnology, Inc. announced its quarterly financial results and entered a sales agreement with TD Cowen to sell $119 million in common stock, following the termination of a previous sales agreement in which they raised $30.6 million from 4.9 million shares sold.

AI Assistant

SANA BIOTECHNOLOGY INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.